News

MVdeltaC, a new therapeutic vaccine, demonstrates promising preclinical immuno-oncolytic activities (Abstract)

Oncovita presents preclinical data on its promising MVdeltaC oncolytic vaccine at SITC Annual Meeting 2022, Nov 8.

Oncovita presents data of MVdeltaC at Société Française d’Immunothérapie du Cancer (FITC), Institut Curie, Paris, 11 octobre 2022